197 related articles for article (PubMed ID: 35806169)
1. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
3. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
5. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Zhao L; Huang S; Mei S; Yang Z; Xu L; Zhou N; Yang Q; Shen Q; Wang W; Le X; Lau WB; Lau B; Wang X; Yi T; Zhao X; Wei Y; Warner M; Gustafsson JÅ; Zhou S
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3673-E3681. PubMed ID: 29592953
[TBL] [Abstract][Full Text] [Related]
7. Different Susceptibilities of Human Melanoma Cell Lines to G2/M Blockage and Cell Death Activation in Response to the Estrogen Receptor β agonist LY500307.
Pontecorvi G; Bellenghi M; Tait S; Tirelli V; Matarrese P; Mattia G; Carè A; Puglisi R
J Cancer; 2022; 13(5):1573-1587. PubMed ID: 35371312
[No Abstract] [Full Text] [Related]
8. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
10. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/ERK/STAT3 signaling.
Ling L; Wen Y; Xiong Y; Liu X; Chen J; Liu T; Zhang B
J Gene Med; 2024 Jan; 26(1):e3571. PubMed ID: 37483091
[TBL] [Abstract][Full Text] [Related]
11. hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells.
Karmakar S; Seshacharyulu P; Lakshmanan I; Vaz AP; Chugh S; Sheinin YM; Mahapatra S; Batra SK; Ponnusamy MP
Oncotarget; 2017 Feb; 8(9):14806-14820. PubMed ID: 28122356
[TBL] [Abstract][Full Text] [Related]
12. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
13. Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
Sang XB; Sun KX; Wang LL; Chen S; Wu DD; Zong ZH; Zhao Y
Oncol Rep; 2016 Dec; 36(6):3267-3274. PubMed ID: 27748937
[TBL] [Abstract][Full Text] [Related]
14. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP; Sareddy GR; Liu Z; Venkata PP; Liu J; Tang W; Altwegg KA; Ebrahimi B; Li X; Tekmal RR; Viswanadhapalli S; McHardy S; Brenner AJ; Vadlamudi RK
Neurooncol Adv; 2021; 3(1):vdab099. PubMed ID: 34485908
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA BACE1-AS is a novel target for anisomycin-mediated suppression of ovarian cancer stem cell proliferation and invasion.
Chen Q; Liu X; Xu L; Wang Y; Wang S; Li Q; Huang Y; Liu T
Oncol Rep; 2016 Apr; 35(4):1916-24. PubMed ID: 26783004
[TBL] [Abstract][Full Text] [Related]
18. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells.
Qin W; Xiong Y; Chen J; Huang Y; Liu T
J Cell Mol Med; 2018 Jul; 22(7):3364-3376. PubMed ID: 29566310
[TBL] [Abstract][Full Text] [Related]
19. HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis.
Zhang Y; Guo J; Cai E; Cai J; Wen Y; Lu S; Li X; Han Q; Jiang J; Li T; Wang Z
Exp Cell Res; 2020 Oct; 395(2):112218. PubMed ID: 32771526
[TBL] [Abstract][Full Text] [Related]
20. LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5.
Ke F; Ren C; Zhai Z; Gao X; Wei J; Zhu Y; Zhi Y
Cell Cycle; 2022 May; 21(10):1020-1033. PubMed ID: 35230909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]